{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T04:26:34Z","timestamp":1782793594258,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Beijing Medical Award Foundation","award":["(No. YXJL-2020-0785-1072)"],"award-info":[{"award-number":["(No. YXJL-2020-0785-1072)"]}]},{"name":"Harbin Medical University Cancer Hospital Haiyan Scientific Research Fund","award":["No. JJZD 2022-10"],"award-info":[{"award-number":["No. JJZD 2022-10"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Mitogen-activated protein kinase 12 (MAPK12), also known as p38\u03b3, is a member of the p38 MAPK family and plays a crucial role in tumor occurrence and invasion. However, there is still uncertainty regarding MAPK12 involvement in diffuse large B-cell lymphoma (DLBCL).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Our study investigated the expression of MAPK12 mRNA in various types of cancer using bioinformatic analysis. Furthermore, we performed immunohistochemistry (IHC) to detect the expression of MAPK12 in patients with DLBCL and compared clinical indicators and survival rates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found that the high expression rate of MAPK12 was 43.1% in DLBCL patients. Several clinical indicators, including IPI scores, Hans classifications, LDH levels, and Ki-67 expression were closely associated with MAPK12 expression. Survival analysis revealed that higher expression of MAPK12 was significantly correlated with shorter progression-free survival (PFS) and overall survival (OS) in DLBCL patients. In addition, both univariate and multivariate analyses revealed IPI score, MAPK12 expression, and rituximab use as the independent OS risk factors (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). To explore the functional role of MAPK12 in DLBCL, weighted gene co-expression network analysis (WGCNA) and gene ontology (GO) were used to confirm the involvement of MAPK12 in the regulation of type II interferon production, positive regulation of lymphocyte proliferation, and other related biological processes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>DLBCL patients have poor prognoses when MAPK12 levels are high, which is expected to be a therapeutic target and prognostic factor.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12094-024-03515-3","type":"journal-article","created":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T17:01:52Z","timestamp":1716310912000},"page":"2966-2978","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A retrospective analysis of the clinicopathological features and prognostic value of MAPK12 protein expression in diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"26","author":[{"given":"Yue","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2286-8866","authenticated-orcid":false,"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,21]]},"reference":[{"key":"3515_CR1","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3322\/caac.20087","volume":"60","author":"CR Flowers","year":"2010","unstructured":"Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-Cell lymphoma. CA Cancer J Clin. 2010;60:393\u2013408. https:\/\/doi.org\/10.3322\/caac.20087.","journal-title":"CA Cancer J Clin"},{"key":"3515_CR2","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identied by gene expression proling. Nature. 2000;403:503\u201311. https:\/\/doi.org\/10.1038\/35000501.","journal-title":"Nature"},{"key":"3515_CR3","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-Cell lymphoma. The New England J Med. 2002;346:1937\u201347. https:\/\/doi.org\/10.1056\/NEJMoa012914.","journal-title":"The New England J Med"},{"key":"3515_CR4","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al.   Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa1801445.","journal-title":"N Engl J Med"},{"key":"3515_CR5","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/ajh.254606","volume":"94","author":"Y Liu","year":"2019","unstructured":"Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94:604\u201316. https:\/\/doi.org\/10.1002\/ajh.254606.","journal-title":"Am J Hematol"},{"key":"3515_CR6","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/2159-8290.CD-20-0174","volume":"10","author":"D Ennishi","year":"2020","unstructured":"Ennishi D, Hsi ED, Steidl C, Scott DW. Toward a new molecular taxonomy of diffuse large B-cell lymphoma. Cancer Discov. 2020;10:1267\u201381. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0174.","journal-title":"Cancer Discov"},{"key":"3515_CR7","doi-asserted-by":"publisher","first-page":"370","DOI":"10.3390\/ijms23010370","volume":"23","author":"L Garc\u00eda-Hern\u00e1ndez","year":"2021","unstructured":"Garc\u00eda-Hern\u00e1ndez L, Garc\u00eda-Ortega MB, Ruiz-Alcal\u00e1 G, Carrillo E, Marchal JA, Garc\u00eda M\u00c1, et al. The p38 MAPK components and modulators as biomarkers and molecular targets in cancer. Int J Mol Sci. 2021;23:370. https:\/\/doi.org\/10.3390\/ijms23010370.","journal-title":"Int J Mol Sci"},{"key":"3515_CR8","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41586-019-1112-8","volume":"568","author":"A Tom\u00e1s-Loba","year":"2019","unstructured":"Tom\u00e1s-Loba A, Manieri E, Gonz\u00e1lez-Ter\u00e1n B, Mora A, Leiva-Vega L, Santamans AM, et al. p38\u03b3 is essential for cell cycle progression and liver tumorigenesis. Nature. 2019;568:557\u201360. https:\/\/doi.org\/10.1038\/s41586-019-1112-8.","journal-title":"Nature"},{"issue":"7","key":"3515_CR9","doi-asserted-by":"publisher","first-page":"3847","DOI":"10.3390\/ijms23073847","volume":"23","author":"M Kciuk","year":"2022","unstructured":"Kciuk M, Gieleci\u0144ska A, Budzinska A, Mojzych M, Kontek R. Metastasis and MAPK pathways. Int J Mol Sci. 2022;23(7):3847. https:\/\/doi.org\/10.3390\/ijms23073847.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3515_CR10","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.3390\/ijms23031108","volume":"23","author":"LJW Pua","year":"2022","unstructured":"Pua LJW, Mai CW, Chung FF, Khoo AS, Leong CO, Lim WM, et al. Functional roles of JNK and p38 MAPK signaling in nasopharyngeal carcinoma. Int J Mol Sci. 2022;23(3):1108. https:\/\/doi.org\/10.3390\/ijms23031108.","journal-title":"Int J Mol Sci"},{"issue":"20","key":"3515_CR11","doi-asserted-by":"publisher","first-page":"7524","DOI":"10.3390\/ijms21207524","volume":"21","author":"O Roche","year":"2020","unstructured":"Roche O, Fern\u00e1ndez-Aroca DM, Arconada-Luque E, Garc\u00eda-Flores N, Mellor LF, Ruiz-Hidalgo MJ, et al. p38\u03b2 and cancer: the beginning of the road. Int J Mol Sci. 2020;21(20):7524. https:\/\/doi.org\/10.3390\/ijms21207524.","journal-title":"Int J Mol Sci"},{"key":"3515_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3389\/fcell.2016.00031","volume":"4","author":"A Esc\u00f3s","year":"2016","unstructured":"Esc\u00f3s A, Risco A, Alsina-Beauchamp D, Cuenda A. p38\u03b3 and p38\u03b4 mitogen activated protein kinases (MAPKs), new stars in the MAPK galaxy. Front Cell Dev Biol. 2016;4:31. https:\/\/doi.org\/10.3389\/fcell.2016.00031.","journal-title":"Front Cell Dev Biol"},{"key":"3515_CR13","doi-asserted-by":"publisher","first-page":"23570","DOI":"10.1074\/jbc.274.33.23570","volume":"274","author":"PW Conrad","year":"1999","unstructured":"Conrad PW, Rust RT, Han J, Millhorn DE, Beitner-Johnson D. Selective activation of p38\u03b1 and p38\u03b3 by hypoxia. J Biol Chem. 1999;274:23570\u20136. https:\/\/doi.org\/10.1074\/jbc.274.33.23570.","journal-title":"J Biol Chem"},{"key":"3515_CR14","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.tibs.2017.02.008","volume":"42","author":"A Cuenda","year":"2017","unstructured":"Cuenda A, Sanz-Ezquerro JJ. p38\u03b3 and p38\u03b4: from spectators to key physiological players. Trends Biochem Sci. 2017;42:431\u201342. https:\/\/doi.org\/10.1016\/j.tibs.2017.02.008.","journal-title":"Trends Biochem Sci"},{"key":"3515_CR15","doi-asserted-by":"publisher","first-page":"3605","DOI":"10.1016\/j.bbadis.2018.08.024","volume":"1864","author":"M Xu","year":"2018","unstructured":"Xu M, Wang S, Wang Y, Wu H, Frank JA, Zhang Z, et al. Role of p38\u03b3 MAPK in regulation of EMT and cancer stem cells. Biochimica et Biophysica Acta BBA - Molecular Basis Dis. 2018;1864:3605\u201317. https:\/\/doi.org\/10.1016\/j.bbadis.2018.08.024.","journal-title":"Biochimica et Biophysica Acta BBA - Molecular Basis Dis"},{"key":"3515_CR16","doi-asserted-by":"publisher","first-page":"18384","DOI":"10.18632\/aging.103708","volume":"12","author":"C Shi","year":"2020","unstructured":"Shi C, Cheng W-N, Wang Y, Li D-Z, Zhou L-N, Zhu Y-C, et al.\u00a0p38\u03b3 overexpression promotes osteosarcoma cell progression. Aging. 2020;12:18384\u201395. https:\/\/doi.org\/10.18632\/aging.103708.","journal-title":"Aging"},{"key":"3515_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.bbrc.2019.07.038","volume":"517","author":"C Su","year":"2019","unstructured":"Su C, Sun Q, Liu S, Wang H, Feng L, Cao Y, et al. Targeting p38\u03b3 to inhibit human colorectal cancer cell progression. Biochem Biophys Res Commun. 2019;517:172\u20139. https:\/\/doi.org\/10.1016\/j.bbrc.2019.07.038.","journal-title":"Biochem Biophys Res Commun"},{"key":"3515_CR18","doi-asserted-by":"publisher","first-page":"118231","DOI":"10.1016\/j.lfs.2020.118231","volume":"258","author":"J Liu","year":"2020","unstructured":"Liu J, Wu Z, Sun R, Nie S, Meng H, Zhong Y, et al. Using mRNAsi to identify prognostic-related genes in endometrial carcinoma based on WGCNA. Life Sci. 2020;258:118231. https:\/\/doi.org\/10.1016\/j.lfs.2020.118231.","journal-title":"Life Sci"},{"key":"3515_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 2008;9:559. https:\/\/doi.org\/10.1186\/1471-2105-9-559.","journal-title":"BMC Bioinform"},{"key":"3515_CR20","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41419-022-04637-8","volume":"13","author":"D-P Yin","year":"2022","unstructured":"Yin D-P, Zheng Y-F, Sun P, Yao M-Y, Xie L, Dou X-W, et al. The pro-tumorigenic activity of p38\u03b3 overexpression in nasopharyngeal carcinoma. Cell Death Dis. 2022;13:210. https:\/\/doi.org\/10.1038\/s41419-022-04637-8.","journal-title":"Cell Death Dis"},{"key":"3515_CR21","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1158\/0008-5472.CAN-19-3281","volume":"80","author":"F Wang","year":"2020","unstructured":"Wang F, Qi X-M, Wertz R, Mortensen M, Hagen C, Evans J, et al. p38\u03b3 MAPK Is essential for aerobic glycolysis and pancreatic tumorigenesis. Can Res. 2020;80:3251\u201364. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-3281.","journal-title":"Can Res"},{"key":"3515_CR22","doi-asserted-by":"publisher","first-page":"6267","DOI":"10.1038\/s41598-018-24631-5","volume":"8","author":"L Li","year":"2018","unstructured":"Li L, Li Y, Que X, Gao X, Gao Q, Yu M, et al. Prognostic significances of overexpression MYC and\/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: a systematic review and meta-analysis. Sci Rep. 2018;8:6267. https:\/\/doi.org\/10.1038\/s41598-018-24631-5.","journal-title":"Sci Rep"},{"key":"3515_CR23","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.critrevonc.2012.12.009","volume":"87","author":"M Martelli","year":"2013","unstructured":"Martelli M, Ferreri AJM, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA, et al. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87:146\u201371. https:\/\/doi.org\/10.1016\/j.critrevonc.2012.12.009.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3515_CR24","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.pathol.2017.08.009","volume":"49","author":"SK Loo","year":"2017","unstructured":"Loo SK, Chng ES, Lawrie CH, Muruzabal MA, Gaafar A, Pomposo MP, et al. DNMT1 is predictive of survival and associated with Ki-67 expression in R-CHOP-treated diffuse large B-cell lymphomas. Pathology. 2017;49:731\u20139. https:\/\/doi.org\/10.1016\/j.pathol.2017.08.009.","journal-title":"Pathology"},{"key":"3515_CR25","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1186\/s12935-020-01491-6","volume":"20","author":"J Lin","year":"2020","unstructured":"Lin J, Yang J, Xu X, Wang Y, Yu M, Zhu Y, et al. A robust 11-genes prognostic model can predict overall survival in bladder cancer patients based on five cohorts. Cancer Cell Int. 2020;20:402. https:\/\/doi.org\/10.1186\/s12935-020-01491-6.","journal-title":"Cancer Cell Int"},{"key":"3515_CR26","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/cac2.12331","volume":"42","author":"P Fajardo","year":"2022","unstructured":"Fajardo P, Taskova M, Mart\u00edn-Serrano MA, Hansen J, Slott S, Jakobsen AK, et al. p38\u03b3 and p38\u03b4 as biomarkers in the interplay of colon cancer and inflammatory bowel diseases. Cancer Commun. 2022;42:897\u2013901. https:\/\/doi.org\/10.1002\/cac2.12331.","journal-title":"Cancer Commun"},{"key":"3515_CR27","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1016\/j.jid.2018.04.030","volume":"138","author":"XH Zhang","year":"2018","unstructured":"Zhang XH, Nam S, Wu J, Chen C-H, Liu X, Li H, et al. Multi-kinase inhibitor with anti-p38\u03b3 activity in cutaneous T-Cell ly mphoma. J Investig Dermatol. 2018;138:2377\u201387. https:\/\/doi.org\/10.1016\/j.jid.2018.04.030.","journal-title":"J Investig Dermatol"},{"key":"3515_CR28","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/onc.2015.158","volume":"35","author":"N Yin","year":"2016","unstructured":"Yin N, Qi X, Tsai S, Lu Y, Basir Z, Oshima K, et al. p38\u03b3 MAPK is required for inflammation-associated colon tumorigenesis. Oncogene. 2016;35:1039\u201348. https:\/\/doi.org\/10.1038\/onc.2015.158.","journal-title":"Oncogene"},{"key":"3515_CR29","doi-asserted-by":"publisher","first-page":"982045","DOI":"10.3389\/fimmu.2022.982045","volume":"13","author":"X Geng","year":"2022","unstructured":"Geng X, Chi K, Liu C, Fu Z, Wang X, Meng L, et al. Interaction of RARRES1 with ICAM1 modulates macrophages to suppress the progression of kidney renal clear cell carcinoma. Front Immunol. 2022;13:982045. https:\/\/doi.org\/10.3389\/fimmu.2022.982045.","journal-title":"Front Immunol"},{"key":"3515_CR30","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.7150\/ijbs.69615","volume":"18","author":"J Patel","year":"2022","unstructured":"Patel J, Xun D, Creswell K, Kim DK, Wu M, Hwang J-W, et al. Loss of RARRES1 function promotes follicular lymphomagenesis and inhibits B cell differentiation in mice. Int J Biol Sci. 2022;18:2670\u201382. https:\/\/doi.org\/10.7150\/ijbs.69615.","journal-title":"Int J Biol Sci"},{"key":"3515_CR31","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1159\/000520803","volume":"107","author":"L Ma","year":"2022","unstructured":"Ma L, Ma Y, Lian A. Involvement of miR-769-5p\/Retinoic acid receptor responder 1 axis in the progression of osteosarcoma: characterization of potential therapeutic targets. Pharmacology. 2022;107:179\u201387. https:\/\/doi.org\/10.1159\/000520803.","journal-title":"Pharmacology"},{"key":"3515_CR32","doi-asserted-by":"publisher","first-page":"1110207","DOI":"10.3389\/fonc.2023.1110207","volume":"13","author":"Y Jia","year":"2023","unstructured":"Jia Y, Guo B, Zhang W, Wang F, Zhang Y, Zhang Q, et al. Pan-cancer analysis of the prognostic and immunological role of GJB2: a potential target for survival and immunotherapy. Front Oncol. 2023;13:1110207. https:\/\/doi.org\/10.3389\/fonc.2023.1110207.","journal-title":"Front Oncol"},{"key":"3515_CR33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13045-015-0116-6","volume":"8","author":"M Lapierre","year":"2015","unstructured":"Lapierre M, Castet-Nicolas A, Gitenay D, Jalaguier S, Teyssier C, Bret C, et al. Expression and role of RIP140\/NRIP1 in chronic lymphocytic leukemia. J Hematol Oncol. 2015;8:20. https:\/\/doi.org\/10.1186\/s13045-015-0116-6.","journal-title":"J Hematol Oncol"},{"key":"3515_CR34","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s13045-021-01166-3","volume":"14","author":"W Wu","year":"2021","unstructured":"Wu W, Liu Y, Zeng S, Han Y, Shen H. Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-\u03b3 signaling and tumor-infiltrating lymphocytes. J Hematol Oncol. 2021;14:160. https:\/\/doi.org\/10.1186\/s13045-021-01166-3.","journal-title":"J Hematol Oncol"},{"key":"3515_CR35","doi-asserted-by":"publisher","first-page":"805195","DOI":"10.3389\/fcell.2021.805195","volume":"9","author":"I Serganova","year":"2022","unstructured":"Serganova I, Chakraborty S, Yamshon S, Isshiki Y, Bucktrout R, Melnick A, et al. Epigenetic, metabolic, and immune crosstalk in germinal-center-derived B-cell lymphomas: unveiling new vulnerabilities for rational combination therapies. Front Cell Develop Biol. 2022;9:805195. https:\/\/doi.org\/10.3389\/fcell.2021.805195.","journal-title":"Front Cell Develop Biol"},{"key":"3515_CR36","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.bcmd.2015.05.012","volume":"55","author":"R Yamaguchi","year":"2015","unstructured":"Yamaguchi R, Kawata J, Yamamoto T, Ishimaru Y, Sakamoto A, Ono T, et al. Mechanism of interferon-gamma production by monocytes stimulated with myeloperoxidase and neutrophil extracellular traps. Blood Cells Mol Dis. 2015;55:127\u201333. https:\/\/doi.org\/10.1016\/j.bcmd.2015.05.012.","journal-title":"Blood Cells Mol Dis"},{"key":"3515_CR37","doi-asserted-by":"publisher","first-page":"31","DOI":"10.31083\/j.fbl2701031","volume":"27","author":"J-Z Qin","year":"2022","unstructured":"Qin J-Z, Xin H, Qi X-M, Chen G. Isoform-specific and cell\/tissue-dependent effects of p38 MAPKs in. Front Bioscience-Landmark. 2022;27:31. https:\/\/doi.org\/10.31083\/j.fbl2701031.","journal-title":"Front Bioscience-Landmark"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03515-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03515-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03515-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T12:37:16Z","timestamp":1731587836000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03515-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":37,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3515"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03515-3","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,21]]},"assertion":[{"value":"6 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This retrospective study involving human participants followed the ethical standards of the institutional research committee (2021\u2013156) and the principles of the 1964 Helsinki Declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients whose data were used in this investigation provided informed consent; for those if a patient was identified retrospectively but had since gone away, their next of kin provided informed consent on their behalf.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}